CSPC Pharmaceutical (HKG:1093) obtained approval to conduct a clinical trial of its SYH2046 tablets in China from the country's National Medical Products Administration, a Friday filing with the Hong Kong bourse said.
The indication for the trial approval is heart failure after acute myocardial infarction.
Preclinical studies have shown the drug to improve cardiac function and reduce adverse cardiac remodeling in disease animal models with a better safety profile.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。